A Systematic Review on NSAID and Tanezumab efficacy in Chronic Lower Back Pain

Abstract

Abstract Chronic back pain is an ailment that impacts people of all ages and lasts longer than 12 weeks. 7.41% of all Years Lost to Disability (YLD) are associated with low back pain, which makes it the pathology responsible for the most YLD, surpassing other chronic conditions such as Diabetes and Depression. Despite the prevalence of drugs such as nonsteroidal anti-inflammatory drugs (NSAIDs), painkillers, and biologics, the types of drugs administered to individuals differ greatly. We collected data from the PubMed database of the PubMed database, National Library of Medicine (NIH), and Google Scholar. Randomized controlled trials (RCTs) that explicitly evaluate the effectiveness of various NSAIDs in adult patients with chronic back pain were selected for this study. After an exhaustive search and examination of numerous publications, only 8 articles met the inclusion criteria. In recent studies that included NSAIDs, they were among the most frequently prescribed medications for the treatment of chronic low back pain. In comparison to placebo, selective COX-II inhibitors such as celecoxib and etoricoxib were found to be efficacious, while valdecoxib was associated with serious side effects. In addition to reducing back pain, COX-II inhibitors with a preference for COX-II, such as aceclofenac and diclofenac, were associated with gastrointestinal side effects. Despite the risk of joint degeneration and accelerated osteoarthritis, intravenous tanezumab may be superior to naproxen and placebo in treating chronic low back pain.